The main purpose of this legislation is to improve the ability of the United States to expand and establish new pharmaceutical manufacturing facilities. It aims to identify and analyze the regulatory challenges that currently hinder this growth and make the U.S. less competitive compared to other countries. The key provisions of the legislation require the Comptroller General of the United States to conduct a comprehensive study. This study will focus on identifying the main regulatory barriers that affect the expansion or establishment of pharmaceutical manufacturing facilities.